As states extend lockdown, here are 6 COVID-proof stocks
Many state governments, over the weekend, have extended lockdown as COVID-19 cases rise across the country to hit a record 3.49 lakh cases in a single day, as on April 25.
The extension of lockdown will hit economic activity and earnings of India Inc in the upcoming June quarter, experts fear.
for FY22. Goldman Sachs and Nomura have cut their forecast for the fiscal year, which began on April 1.
Investors will be better off investing in stocks that are COVID-proof and should be able to show quarter-on-quarter (QoQ) growth.
Pharma is in a clear uptrend and it is likely to perform, going forward as well, whereas auto is likely to see some bounce-back. Metals have been the star performer so far in the April series. However, most of them is priced in and it too can see some consolidation,” Jay Thakkar, VP and Head of Equity Research at Marwadi Shares and Finance Ltd, told Moneycontrol.
“The FMCG sector, like that of pharma, is likely to perform well in the short to medium term. Pathology labs are likely to perform well in the short to medium term,” he said.
The Indian market is down by about 9 per cent from the highs, which factors in the partial lockdown in many states as well as slowdown in industrial activity and demand trends.
The ongoing slowdown is bound to impact the June quarter earnings, but on a YoY basis, the results will be strong. The impact will be visible on a sequential basis.
“The second wave is likely to peak by end-April and then show a steady decline, as many models suggest. For FY22, a GDP growth of 10 per cent is achievable,” Dr VK Vijayakumar, Chief Investment Strategist, Geojit Financial Services, told Moneycontrol.
“Since 65 percent of Nifty earnings have global linkage, and segments like IT and metals are doing well, Q1 earnings will not be hit hard,” he said.
The vaccination drive will be opened up for all citizens above the age of 18 from May 1, the Union government announced on April 19. The immunisation drive was so far restricted to citizens aged above 45 years.
“Opening up of vaccines for everyone above 18 years of age brings in a huge positive sentiment among people. The government is also pushing up the manufacturing infrastructure. It has approved many other vaccines as well,” Divam Sharma, Co-founder, Green Portfolio, told Moneycontrol.
“The last 2-3 quarters of FY21 had reflected the strength of our country and its economy. Vaccination drive and lesser restrictions will lead to continuity in the double-digit GDP growth expectations and many listed businesses will continue to outperform, resulting in markets gaining further momentum,” he said.
Download our App to get knowledge updates: https://play.google.com/store/apps/details?id=com.app.gstmitraa
Join Our Telegram Channel for more updates: https://t.me/praveengst
Comments
Post a Comment